VCNX Insider Trading (Vaccinex)
Insider Ownership Percentage: 47.60%
Insider Buying (Last 12 Months): $2,126,399.01
Insider Selling (Last 12 Months): $0.00
Vaccinex Share Price & Price History
Current Price: $1.08
Price Change: ▲ Price Increase of +0.02 (1.89%)
As of 06/30/2022 01:00 AM ET
Tailor an Options Trading Strategy to Fit Your Needs
From RJO Futures | Ad
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
Vaccinex Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/23/2022 | Strydonck Gerald E Van | Director | Buy | 20,000 | $1.32 | $26,400.00 | |  |
| 1/27/2022 | Jacob B. Frieberg | Director | Buy | 90,090 | $1.11 | $99,999.90 | | |
| 1/27/2022 | Maurice Zauderer | CEO | Buy | 1,801,801 | $1.11 | $1,999,999.11 | | |
| 7/10/2020 | Albert Friedberg | Director | Buy | 1,126,760 | $3.55 | $3,999,998.00 | 439,555 | |
| 3/30/2020 | Albert Friedberg | Director | Buy | 9,000 | $4.02 | $36,180.00 | | |
| 3/26/2020 | Albert Friedberg | Director | Buy | 3,000 | $4.42 | $13,260.00 | | |
| 3/17/2020 | Albert Friedberg | Director | Buy | 7,040 | $4.01 | $28,230.40 | | |
| 1/23/2020 | Albert Friedberg | Director | Buy | 982,318 | $7.03 | $6,905,695.54 | | |
| 1/23/2020 | Maurice Zauderer | CEO | Buy | 98,231 | $7.03 | $690,563.93 | | |
| 7/30/2019 | Albert Friedberg | Director | Buy | 1,838,235 | $4.08 | $7,499,998.80 | | |
| 7/30/2019 | Maurice Zauderer | Insider | Buy | 183,824 | $4.08 | $750,001.92 | | |
| 7/26/2019 | Albert Friedberg | Director | Buy | 1,052 | $3.99 | $4,197.48 | | |
This Has Won 99.1% Of Trades Over 3 Years
From Investing Daily | Ad
Video reveals the most powerful trade you’ve NEVER heard of. Released every Tuesday, it could DOUBLE your money by Friday.
In past 3 years, it’s won 321 out of 324 of these trades, with the majority making 100%+ every 3-10 days.
See how a simple 10-minute trade on Tue could double your money by Fri.
Watch Video Now For Full Details.
>>>
Vaccinex Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/17/2022 | Worth Venture Partners LLC | 66,856 | $88K | 0.0% | N/A | 0.157% |  |
| 5/13/2022 | Vanguard Group Inc. | 727,265 | $0.96M | 0.0% | +16.7% | 1.705% | |
| 5/12/2022 | AIGH Capital Management LLC | 2,081,801 | $2.63M | 0.6% | N/A | 4.880% | |
| 11/16/2021 | Telemetry Investments L.L.C. | 132,500 | $0.29M | 0.4% | +10.4% | 0.430% | |
| 11/15/2021 | Natixis | 31,895 | $69K | 0.0% | N/A | 0.104% | |
| 11/12/2021 | Oppenheimer & Co. Inc. | 31,751 | $69K | 0.0% | -24.3% | 0.103% | |
| 9/17/2021 | Virtu Financial LLC | 38,026 | $0.11M | 0.0% | +103.9% | 0.123% | |
| 8/16/2021 | Point72 Asset Management L.P. | 395,522 | $1.11M | 0.0% | N/A | 1.390% | |
| 8/16/2021 | Telemetry Investments L.L.C. | 120,000 | $0.34M | 0.5% | +14.3% | 0.422% | |
| 8/16/2021 | State Street Corp | 67,200 | $0.19M | 0.0% | N/A | 0.236% | |
| 8/13/2021 | Geode Capital Management LLC | 104,114 | $0.29M | 0.0% | +59.4% | 0.366% | |
| 8/13/2021 | Vanguard Group Inc. | 600,624 | $1.68M | 0.0% | +145.9% | 2.111% | |
| 5/19/2021 | Virtu Financial LLC | 18,652 | $56K | 0.0% | N/A | 0.066% | |
| 5/17/2021 | Goldman Sachs Group Inc. | 20,447 | $61K | 0.0% | -41.9% | 0.072% | |
| 5/13/2021 | Bank of New York Mellon Corp | 17,954 | $54K | 0.0% | N/A | 0.063% | |
| 5/12/2021 | Geode Capital Management LLC | 65,331 | $0.19M | 0.0% | N/A | 0.230% | |
| 5/12/2021 | UBS Group AG | 28,708 | $86K | 0.0% | N/A | 0.101% | |
| 5/10/2021 | Oppenheimer & Co. Inc. | 42,951 | $0.13M | 0.0% | -24.3% | 0.151% | |
| 5/4/2021 | Institute for Wealth Management LLC. | 20,000 | $60K | 0.0% | N/A | 0.070% | |
| 2/17/2021 | Tacita Capital Inc | 13,574 | $28K | 0.0% | N/A | 0.061% | |
| 2/16/2021 | Squarepoint Ops LLC | 40,583 | $84K | 0.0% | N/A | 0.181% | |
| 2/11/2021 | Oppenheimer & Co. Inc. | 56,751 | $0.12M | 0.0% | +141.1% | 0.254% | |
| 12/11/2020 | Virtu Financial LLC | 26,249 | $47K | 0.0% | N/A | 0.117% | |
| 10/20/2020 | Wedbush Securities Inc. | 31,000 | $55K | 0.0% | N/A | 0.154% | |
| 5/18/2020 | MSD Partners L.P. | 1,161,855 | $4.65M | 1.3% | -5.2% | 7.102% | |
| 11/27/2019 | MSD Partners L.P. | 1,225,490 | $8.79M | 1.2% | N/A | 8.247% | |
| 10/31/2019 | Oppenheimer & Co. Inc. | 28,900 | $0.21M | 0.0% | +82.9% | 0.194% | |
| 8/10/2019 | Oppenheimer & Co. Inc. | 15,800 | $87K | 0.0% | N/A | 0.138% | |
| 6/30/2019 | Creative Planning | 10,000 | $55K | 0.0% | N/A | 0.087% | |
| 2/15/2019 | Millennium Management LLC | 73,384 | $0.28M | 0.0% | -12.4% | 0.639% | |
| 2/14/2019 | Telemetry Investments L.L.C. | 14,720 | $54K | 0.0% | +26.3% | 0.128% | |
| 12/13/2018 | Vanguard Group Inc | 49,311 | $0.34M | 0.0% | N/A | 0.430% | |
| 11/23/2018 | Vanguard Group Inc. | 49,311 | $0.34M | 0.0% | N/A | 0.430% | |
| 11/15/2018 | Nexthera Capital LP | 17,047 | $0.12M | 0.0% | N/A | 0.148% | |
| 11/14/2018 | Perceptive Advisors LLC | 50,000 | $0.37M | 0.0% | N/A | 0.436% | |
| 11/9/2018 | Bank of New York Mellon Corp | 17,048 | $0.12M | 0.0% | N/A | 0.149% | |
Data available starting January 2016
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Read More on Vaccinex
Volume
64,827 shs
Average Volume
708,569 shs
Market Capitalization
$46.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.09
Who are the company insiders with the largest holdings of Vaccinex?
